GILD Stock Recent News

Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago.

The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.

Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.

Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.